Condition
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) clinical trials that are recruiting, at sites in 14 countries (most in United States (3), Canada (2), Thailand (1)). By phase: Phase 4 (1), Phase 2 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 14Countries
Newest Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Cardiovascular Risk in Thai MASLD Patients: Coronary Calcium Scores | — | Bangkok, Bangkoknoi | Recruiting | Oct 8, 2026 |
| ALN-PNP with or without a GLP-1/GIP receptor agonist in adults with PNPLA3-related MASLD | Phase 2 | Tucson, Arizona and 8 other locations | Recruiting | Apr 14, 2026 |
| Using niacin to shift fat into body fat and away from the liver | — | Sherbrooke, Quebec | Recruiting | Feb 24, 2025 |
| Improving liver health through metabolic surgery or medication | Phase 4 | Phoenix, Arizona and 21 other locations | Recruiting | Apr 19, 2024 |
| ALN-PNP safety and tolerability in healthy adults and adults with MASLD | Phase 1/2 | Glendale, California and 5 other locations | Recruiting | Dec 13, 2022 |
All recruiting trials (5)
-
Cardiovascular Risk in Thai MASLD Patients: Coronary Calcium Scores
This study tests how well common cardiovascular risk tools align with coronary calcium scores in Thai adults with MASLD who have no heart symptoms.
-
ALN-PNP with or without a GLP-1/GIP receptor agonist in adults with PNPLA3-related MASLD
This study tests ALN-PNP, with or without tirzepatide, to see if it can reduce liver fat in adults with PNPLA3-related MASLD.
-
Using niacin to shift fat into body fat and away from the liver
This study will test whether daily niacin can lower liver fat and increase storage of dietary fat in body fat in people age 50–80 with MASLD and abdominal obesity.
-
Improving liver health through metabolic surgery or medication
This study is testing whether metabolic surgery or medication can improve liver health in people with liver disease and obesity.
-
ALN-PNP safety and tolerability in healthy adults and adults with MASLD
This first-in-human trial tests whether the experimental drug ALN-PNP is safe and well tolerated in healthy adults and in adults with MASLD who carry a specific PNPLA3 gene variant.
Related topics
Quick answers
How many Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 14 countries. The most sites are in United States (3 trials), Canada (2 trials), Thailand (1 trial), Brazil (1 trial), Finland (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 4: 1, Phase 2: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.